Clinical and dynamic circulating cytokines profile features of long-term progression-free survival benefit to immune checkpoint inhibitors in advanced non–small cell lung cancer

Abstract Background Immune checkpoint inhibitors (ICIs) offer durable progression-free survival (PFS) benefit in a subset of patients with advanced non-small cell lung cancer (NSCLC). However, the predictors of long-term PFS (LTPFS) remain unclear. Methods Advanced NSCLC patients receiving first-lin...

Full description

Saved in:
Bibliographic Details
Main Authors: Jia-Yi Deng, Ming Gao, Xue Fan, Hong-Hong Yan, Wei-Chi Luo, Ming-Yi Yang, Xiao-Rong Yang, Zhi-Hong Chen, Chong-Rui Xu, Qing Zhou
Format: Article
Language:English
Published: Springer 2025-04-01
Series:Cancer Immunology, Immunotherapy
Subjects:
Online Access:https://doi.org/10.1007/s00262-025-03984-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items